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Abstract In severepneumonia, the applicationofgranulocyte-colonystimulating factor (G-CSF)was associatedwith
reduced complications possibly by an induction of anti-inflammatory cytokines. It is not clear, whether G-CSF induces
interleukin-10 (IL-10) synthesis in neutrophils. In a randomized study,15 patients with severe community acquired pneu-
moniawere treated either by a single dose of G-CSF and antibiotic therapy (n=8) or antibiotics alone (n=7).Messenger
ribonucleic acid (mRNA) expression of IL-10 and tumor necrosis factor alpha of peripheral blood leukocytes was mea-
sured using in-situ hybridization (ISH) and reverse-transcription-polymerase-chain-reaction (RT-PCR). In addition, the
cytokinerelease of lipopolysaccharide (LPS)-stimulatedwholebloodwasmeasuredby ELISA.Wedetectedincreased IL-
10 mRNAby ISH (14078% vs. 1175%, Po0.01) and RT-PCR (126716% vs. 2873 %, Po0.01) in the G-CSF-treated
group only. In contrast,LPS-stimulatedwhole blood cells in vitro released significantly less IL-10 compared to the control
group (38.279.7 vs.14.876 pg/ml,Po0.02).Therewasno significanteffecton IL-10 serumproteinlevels andtheTNF-
a release andexpression.IL-10mRNAwasdetectedpredominantlyinclusterdesignation 66b (CD66b) positivenucleated
blood cells indicating that polymorphonuclear leukocytes are the main source of IL-10 expression after G-CSF stimula-
tion.G-CSF induces transcription of IL-10 mRNAinneutrophilswithout increased release.Thismay be due to posttran-
scriptional effects.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Despite of antibiotic treatment, the mortality of severe
community acquired pneumonia (SCAP) especially in pa-
tients with severe comorbidity remains high (1). A possi-
ble explanation for this is an imbalance of pro- and anti-
in£ammatory cytokines (2).Tumor necrosis factor alpha
(TNF-a) is a keypro-in£ammatorycytokine. Itplays a cri-
tical role in the resolution and outcome of infections
(2,3): higherTNF-a serumlevels are associatedwithhigh-
ermortality in patientswith sepsis syndrome (4). Several
studies investigated anti-TNF-a strategies tomodify out-
come of infections, but even complete inhibition of TNF-
a receptors did not alleviate the disease process (5).
Strategies thatmodulate the cytokine cascade by down-
regulation but not complete inhibition of pro-in£amma-
tory cytokines might have advantages (6^8). In animalReceived 5 February 2002, accepted in revised form 27 May 2002
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stimulating factor (G-CSF) showed bene¢cial e¡ects (9).
Application ofG-CSF in healthy volunteers causes anup-
regulation of anti-in£ammatory factors like solubleTNF-
a receptor p55 and interleukin-1 (IL-1) receptor antago-
nist (IL-1RA) and a reduced TNF-a release (10,11). Less is
known about the in£uence of G-CSF on IL-10 expression
in pneumonia patients.Data regarding IL-10 are inconclu-
sive: decreased (11) as well as increased IL-10 protein re-
lease were described (12). Moreover, the in£uence of G-
CSF on the gene activity of IL-10 and TNF-a is not clear.
We investigated the in£uence of G-CSF on cytokine
messenger ribonucleic acid (mRNA) of IL-10 and TNF-a
in patientswith SCAPusing in-situ hybridization (ISH) for
detection of intracellular mRNA and reverse-transcrip-
tion-polymerase-chain reaction (RT-PCR) as control
method. Moreover, we measured IL-10 and TNF-a re-
lease of lipopolysaccharide (LPS)-stimulated whole
blood and the serum concentration using ELISA. We
asked the following questions: Does G-CSF upregulate
IL-10 expression and release in SCAP? Which cells are
52 RESPIRATORYMEDICINEthepredominant source of IL-10mRNA?DoesG-CSF in-
hibit the expression and release of TNF-a?
METHODS
Study design
These data were collected in the context of a prospec-
tive, open, randomized clinical study in patients with
SCAP and comorbidity.The diagnosis of pneumonia was
based on clinical symptoms and laboratory signs of infec-
tion [such as fever4381C, purulent sputum, elevated er-
ythrocyte sedimentation rate (ESR), C-reactive protein
(CRP)] together with thepresence of neworprogressing
opacities on a chest radiograph. The patients were ran-
domized in a G-CSF group (n=8) and a control group
(n=7) receiving a standard antibiotic therapy.The mean
agewas 62.974.5 years (mean7SEM) in theG-CSF group
and 72.974 years in the control group, respectively
(P=0.19). In nine of the 15 patients (¢ve of eight patients
in the G-CSF group, four of seven patients in the control
group), the causative pathogens were identi¢ed: Strepto-
coccus pneumoniae was isolated in six patients (n=3 in
both groups),Haemophilus in£uenzae in two (n=1in each
group) and Escherichia coli in1G-CSF treated patient.
After randomization and (if applicable) G-CSF admin-
istration, a prede¢nedantibiotic treatmentwas initiated.
This consistedof erythromycin (2^31g i.v.)+ceftriaxon
(12 g i.v.). Patients with antibiotic pretreatment were
treated alternatively by a quinolone or carbapenem.
Demographic data of the patients are given inTable 1.
Patient characteristics were comparable in both groups.
The severityof pneumonia as assessedby theCPIS-score
(13) was 670.4 in the G-CSF-treatedgroup compared to
4.470.8 in the control group (P=0.19).CRP as marker of
the systemic in£ammatory responsewas142717mg/l in
G-CSF treated patients compared to115718 in the con-
trol group (P=0.59). Prior to the initiation of antibiotic
treatment, a single dose of 300mg (o60kg) or 480mg
(X60kg) recombinant G-CSF (¢lgrastim, speci¢c activ-TABLE 1. Demographic data
Group Age CPIS score
G-CSF 62.974.5 670.4
Control 72.974 4.470.8
UnderlyingdiseasesintheG-CSF-treated patientswere:COPD
vious cardiac surgery, n=3; tachyarrhythmia, n=2; diabetesme
breast, n=1; aortic stenosis, n=1; aortic regurgitation, n=1; my
Underlying diseases in the patients with standard treatment (con
disease, n=3; renal failure, n=3; COPD, n=2; hypertension, n=
liver cirrhosis, n=1; asbestosis, n=1; esophageal varicosis, n=1;
monaryemphysema, n=2.All data are given asmean7SEM.ity: 30106U/ml) was administered subcutaneously.
After G-CSF treatment, the leukocyte and neutrophil
count increased signi¢cantly (Po0.02).The trial was per-
formed in a randomized order. Before and12, 24, 48 and
96h after G-CSF application, venous blood was drawn
for white blood cell (WBC) count, whole blood stimula-
tion assay, cytokine mRNA and serum cytokine levels.
The study was approved by the ethics committee of the
Medical University, Luebeck, and all patients gave writ-
ten informed consent.
ISH fromwhole blood smears fordetection of intracellular
TNF-a and IL-10 mRNA
For ¢xation, EDTA-blood was treated as described be-
fore (14). Cells were permeabilized byTarget Retrievalt
(Dako, Hamburg, Germany) (20min, 951C) followed by
brie£y washing with diethyl-pyrocarbonate (DEPC)-
treated deionized water at room temperature (rt). The
strong endogenous peroxidase activity was inhibited by
0.6% H2O2 in methanol (Merck, Darmstadt, Germany)
(45min, rt). ISHwas performedusing 20ml of hybridmix-
ture, containing forTNF-a (di¡erent concentrations for
IL-10 in brackets) 0.1% SDS, 5 (2.5 ) SSC, 5% dextran-
sulfate, 14% (7%) formamide (Sigma, Deisenhofen, Ger-
many), 2% blocking solution, 0.1% bovine serum albumin,
250mg/ml ¢sh sperm DNA, 250mg/ml t-RNA, (Roche
Molecular Biochemicals, Mannheim, Germany), 5ng/ml
(7 ng/ml) of each oligonucleotide probe. Hybridization
was performed on the Misha in-situ thermocycler using
the following protocol: 10min denaturation at 951C fol-
lowed by incubation for 10h at 451C for TNF-a and at
421C for IL-10. Posthybridization for TNF-a was per-
formed as described before at 451C (14). IL-10 probes
were washed once in 0.1% SDS/0.5 SSC (10min, rt)
and two times in 0.1% SDS/0.5 SSC (451C, 10min) fol-
lowed by brie£y washing withTBST (Dako) in the Misha
Wash Modul (Shandon). For detection, the biotinyl-tyra-
mide signal ampli¢cation procedure (GenPoint, Dako)
was applied using 3-amino-9-ethyl carbazol (AEC)PMN/nl CRPmg/l PO2/FiO2
8.770.8 142717 242.9715.9
8.971 115718 2197202
, n=4; coronaryarterydisease, n=4; hypertension, n=3; pre-
llitus, n=3; peripheral vascular disease, n=1; carcinoma of the
ocardial infarction, n=1; prostatic cancer, n=1; seizures, n=1.
trol group) were: myocardial infarction, n=6; coronary artery
2; diabetesmellitus, n=2; stroke, n=2; gastric resection, n=2;
M.Parkinson, n=1; anemia, n=1; hyperthyroidism, n=1; pul-
G-CSF INCREASES IL-10 MRNAINNEUTROPHILS 53(Dako) as the chromogen for up to 40min as described
before (15,16).Controls were performed to ensure speci-
¢city of results by using para⁄n-embedded human lung
tissue and included the omission of probe or primary
antibody.
Twenty di¡erent areas per slide were randomly cho-
sen for taking digital pictures. Image analysis for determi-
nation of the background-corrected integrated optical
density (IOD) of the signals in positive cells was per-
formed with ImagePro Plust (Media Cybernetics,
U.S.A.).Datas were calculated to mean.
Biotin-labelled oligonucleotide probes: IL-10: 255-
1.FOR: 50 -AGG ACT TTA AGG GTT ACC TGG GTT
G-30, 408-1.FOR: 50 -TAC GGC GCT GTC ATC GAT
TTC TTC C-30, 196 -7.FOR: 50 -AGA CTT TCT TTC
AAA TGA AGG ATC AGC TGG-30, 475-11.FOR: 50 -
CCT TTA ATA AGC TCC AAG AGA AAG GCA-30.
TNF-a: 336R: 50 -GGG GTT CGA GAA GATGAT CTG
ACT G-30. 375R: 50 -TGA GGG TTT GCT ACA ACA
TGG GCT A-30. 450R: 50 -TTA TCT CTC AGC TCC
ACGCCATTG-30.
Clusterdesignation 66b (CD66b)-antibody staining after
ISH detection forcell identi¢cation
Permeabilized cells were incubated in 1:100 diluted pri-
mary antibodymouse-anti-human-CD66b (Pharmingen,
SanDiego,U.S.A.) (60min, rt) followedbyTBSTwashing.
Using rabbit-anti-mouse-POD-antibody diluted 1:100 in
antibody diluent (Dako) (30min, rt) for detection fol-
lowed by a three times washing withTBSTagain. Slides
were treatedwithbiotinyl-tyramide (15min, rt) andwith
1:100 diluted anti-biotin-antibody (Roche M. B.) (30min,
rt). Staining byNBT/BCIP (RocheM.B.) up to 30min (14).
The digitized pictures of the immunohistochemistry and
ISHwere overlayedby image analysis IPP3.0t (MediaCy-
bernetics).
RT-PCR
RNA isolation (RNeasy Blood Mini KittQiagen,Hilden,
Germany) and degradation of genomicDNA (Gibco)was
performed using commercially available assays as de-
scribed by the manufacturer. All incubations were per-
formed in a thermocycler (PTC-200, MJ Research
Biozym, Hess. Oldendorf, Germany). For reverse tran-
scription, 8ml total RNA and150ng Random Hexamers
(Roche M. B.) were incubated (701C, 10min). Reverse
transcription was done with reverse transcriptase II
(Gibco) according to the manufacturers instructions in-
cluding 1ml RNAse inhibitor (Pharmacia Biotech, Frei-
burg,Germany). Solution was diluted by 80ml H2O. For
PCR ampli¢cation of GAPDH and TNF-a 10ml cDNA
and 40ml PCR mixture including 1.4mM TaqStart anti-
body solution (Clontech, Palo Alto, U.S.A.) were incu-
bated at the same conditions as described before (14).The conditions for IL-10 were the same using 4.5mM
MgCl2, 34 cycles and an annealing temperature of 591C.
Primer sequences: TNF-a: 50 -AGG CAG TCA GAT
CAT CTT CTC GAA C-30; 50 -TTG AAG AGG ACC
TGGGAG TAG ATG A-30; GAPDH: 50 -CCATGG AGA
AGGCTGGGG-30, 50 -CTA AGC AGT TGG TGG TGC
A-3’ IL-10: 50 -TTTCTC TTGGAGCTTATTAAAG-30,
50 -AAGACT TTC TTTCAA ATGAAGG-30.
For analysis, the RT-PCRproductsweremonitoredby
electrophoresis in 2% agarose as described before (14).
The intensity of the bandsweremeasuredby densitome-
try (GelPro Analyzert, Media Cybernetics). The back-
ground-corrected IOD of each fragment was divided by
the IOD of the corresponding GAPDH-bands (ratio) and
calculated to mean.
ELISA formeasurement ofcytokine release and serum
levels of IL-10
Whole blood was incubated as described before (11). For
detection of cytokines in LPS-stimulated whole blood
and serumwe used commercially available assays for hu-
manTNF-a (lower detection limit 1pg/ml), human IL-10
(5pg/ml) andhumanultrasensitive IL-10 (208 fg/ml)ELISA
kits (Cytoscreen Immunoassay Kit, Biosource, CA,
U.S.A.).
Statistical analysis
Data aregiven asmean7SEM if nototherwise stated.Dif-
ferences in the time course of parameters after G-CSF
application were tested by analysis of variance for re-
peated measures (ANOVA). Wilcoxon signed rank test
was used for paired samples, Mann^Whitney-U-test for
comparison of independent groups. Correlations were
made with Spearman’s rank correlation. Calculations
were carried out with Statistica for Windows, version
5,1997. Avalue Po0.05 was considered signi¢cant.
RESULTS
Twelve hours after G-CSF application, IL-10 mRNA in-
creased by14078% asmeasured by ISH [Figs.1and 2(a),
Po0.01] and by 126716% as detected by RT-PCR [Fig.
2(b), Po0.01]. In both methods, the mRNA amount
decreased after 24^96h to the baseline level. In the con-
trolgroup, no signi¢cantchanges from t0 to t1with regard
to mRNA amounts were detected (ISH: 1175%; RT-
PCR:2873%).The serumconcentrations of IL-10were
not in£uencedbyG-CSF [Fig. 2(c),P=0.24].Therelease of
IL-10 from LPS-stimulated blood in vitro was signi¢cantly
decreased12hafterG-CSF application [Fig. 2(d),Po0.02].
The neutrophil count increased signi¢cantly after G-
CSF application [Fig. 3, Po0.01]. IL-10 mRNA correlated
signi¢cantly with the neutrophil count in both groups
12 h0 h
0 h 12 h
(A)
(B)
FIG. 1. ISH of blood smears (A: IL-10,B:TNF-a) before and12 h after G-CSF application.The intensity of IL-10 mRNA positive cells
increased after G-CSF treatment, whereas the intensityof TNF-a positive cells didnot increase (magni¢cation1:250).
54 RESPIRATORYMEDICINE(r=0.38, Po0.04 in the G-CSF group and r=0.43, Po0.05
in the control group).
Doublestaining ISH slides with CD66b, a marker for
granulocytes, revealed that IL-10 mRNA was located
predominantly in nucleated blood cells positive for
CD66b.Thus, mRNA positive cells were predominantly
neutrophils (Fig. 4).
Using RT-PCRTNF-amRNAwas not in£uencedbyG-
CSF treatment (P=0.19).We could not detect any di¡er-
ences of TNF-amRNAby ISH in both groups.TheTNF-a
release from stimulated whole blood detected by ELISA
remained una¡ected by G-CSF (Figs.1and 5).
DISCUSSION
The cytokinesTNF-a and IL-10 play a crucial role in initia-
tion and resolution of in£ammatory processes in pneu-
monia. In a mouse model of acute pneumococcal
pneumonia,TNF-awas necessary for thebacterial clear-
ance (5). On the other hand, systemic infection can in-
duce an overwhelming pro-in£ammatory cytokine
response (2). G-CSF may attenuate the course of infec-
tion by reduction of the pro-in£ammatory cytokine re-
sponse and stimulation of anti-in£ammatory cytokines
(11). Several studies investigated the in£uence of G-CSF
on animals with pneumonia and observed a reduced
mortality (12). In G-CSF-treated patients with SCAP,
Nelson et al. reported a reduced complication ratewith-
out a reduction ofmortality (17). A similar e¡ectwas re-ported regarding IL-10-treatedmice with sepsis (6).This
anti-in£ammatory cytokine inhibits macrophage and
polymorphonuclear leukocyte (PMN) phagocytic activ-
ity and suppresses the production of a variety of pro-in-
£ammatory cytokines (18). In this study, we investigated
the in£uence of G-CSF on the gene activity of IL-10 and
TNF-a using ISH with subsequent signal ampli¢cation
and RT-PCR.TNF-a and IL-10 mRNAwere detected by
ISH inwhole blood smears.
ISH has been used for mRNA detection before (19). A
limitation of this method is the low sensitivity (16). To
overcome this problem, we used ISH with subsequent
signal ampli¢cation. For achieving maximum sensitivity
and because endogenous biotin was not a problem con-
cerning the cells under investigation we used the bioti-
nyl-tyramid signal ampli¢cation system instead of the
dextran-polymer-based Envision+signal-enhancement
system as for the formerone ithasbeen shown that even
single-copy genes can be detected (15,16).We observed a
more than twofold increased IL-10 mRNA 12h after
G-CSF application in pneumonia patients. Similar results
were described by Mielcarek et al. (12), who observed a
tenfold increase of IL-10 mRNA in whole blood after G-
CSF application in healthy volunteers. Michon et al. (20)
documented an increased IL-10mRNAin sixof13G-CSF-
treated children with underlyingmalignancy followed by
autologous haematopoietic stem cell rescue.
In contrast to the ¢ndings concerning mRNA, serum
IL-10 levels did not increase signi¢cantly in our study.
After LPS stimulation ofwholeblood invitro, IL-10release
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FIG. 2. Densitometricmeasurementof IL-10 mRNApositive cellsmarked by ISH [IOD, (a)] and IL-10 mRNAof whole blood leuko-
cytesusing RT-PCR [IOD-ratio,(b)].ThepatientsreceivingG-CSF showeda signi¢cantlyincreasedconcentrationof IL-10mRNAcom-
paredtopatientsreceivingplacebo (ISH:Po0.01;RT-PCR:Po0.01).Inpatients serum,IL-10 proteinlevelsdidnotincrease signi¢cantlyin
the G-CSF-treated group [(c), P=0.24].The concentrations of IL-10 in supernatants of LPS-stimulated blood cells (d) were signi¢cantly
reducedby G-CSF (Po0.02).A:G-CSF-and antibiotic-treatedgroup.B: controlgroupwith standard antibiotic treatment.
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FIG. 3. Neutrophils increased signi¢cantly after G-CSF treatment (Po0.01).IL-10 mRNA andneutrophil countof G-CSF group cor-
related signi¢cantly (r=0.54, Po0.01).
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FIG. 4. Picture1FIL-10 mRNAcontaining cellsmarked by ISH.Picture 2Fthe same cells incubatedwith antibody staining against
CD66b, amarker forneutrophils (magni¢cation1:400).
56 RESPIRATORYMEDICINEwas even decreased after G-CSF application. Previous
studies reported con£icting results.Mielcareket al. mea-
suredincreased IL-10 levels in supernatants of LPS-stimu-
lated whole blood (12). Hartung et al. observed a slightly
increased release after whole blood LPS-stimulation in
healthy volunteers. They assumed that this may be due
to an increased leukocyte count (10). After LPS-stimula-
tion,Dalho¡ et al. measured signi¢cantly decreased IL-10
levels in healthy volunteers treated with G-CSF (11).
These di¡erent results on gene and protein level in this
studies may be explained by di¡erences in stimulation,
cell counts or posttranscriptional e¡ects. To detect the
major source of IL-10 mRNA, we stained the ISH blood
smears with CD66b, which is a speci¢c marker for neu-
trophils and eosinohils (21).Most of the IL-10mRNA con-
taining cells were CD66b positive. The positive
correlations of IL-10 expression and neutrophil counts in
both groups support these ¢ndings. Whether neutro-
phils are able to synthesize IL-10, is discussed contro-
versely (22). Reglier et al. (23) and Keel et al. (24)
investigatedhuman polymorphonuclear cells in vitrowith
di¡erent stimuli and couldnotdetect any IL-10mRNAor
protein production. However, other authors observed
IL-10 in supernatants of cultures from highly puri¢ed hu-
man neutrophils from severely injured patients (25). Ro-manietal. (26) andMencaccietal. (27) noticed a low level
IL-10 secretion of mouse neutrophils stimulated with
candida albicans. From our data, we conclude that G-
CSF induces the transcription of IL-10 mRNA predomi-
nantly in neutrophils.They were the major source of IL-
10 mRNA but neutrophils obviously play a minor role in
releasing this protein due to a restricted translation.The
mechanisms of posttranscriptional regulation of IL-10 are
poorly understood.The stability of mRNA, that is regu-
lated on gene level, seems to be an important factor in
the regulation of IL-10 translation (28,29).
Our data suggest that G-CSF application does not in-
£uenceTNF-amRNA. Aprevious study reported similar
results regardingTNF-a mRNA (20).TNF-a release was
also not in£uencedby G-CSF in our study.Other studies
described a signi¢cantly reduced TNF-a protein release
after treatment with G-CSF in experimental models
and in healthy volunteers (11,30). In a recent study, Kita-
bayashi et al. speculated that the lower protein level of
TNF-a without mRNA downregulation may be due to a
directposttranscriptional e¡ectofG-CSF onTNF-a pro-
duction in peripheral blood cells (31).
In conclusion, we investigated the e¡ect of G-CSF on
IL-10 mRNA and protein in patients with SCAP using
ISH, RT-PCR and ELISA.G-CSF induces transcription of
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FIG. 5. Densitometricmeasurementof TNF-amRNAusing RT-PCR and ISH (a and b). mRNAwas not in£uenced by G-CSF treat-
ment (RT-PCR:P=0.19; ISH: P=0.97).TheTNF-a release from stimulatedwhole bloodremaineduna¡ected by G-CSF [(c), P=0.09]. A:
G-CSF-treatedgroup.B: controlgroupwith standard antibiotic treatment.
G-CSF INCREASES IL-10 MRNAINNEUTROPHILS 57IL-10mRNA in neutrophils, but the protein level remains
unchanged.Neutrophils express IL-10 but theydo not re-
lease IL-10 in measurable amounts, possibly due to post-
transcriptional restriction. Therefore, the known
upregulation of anti-in£ammatory factors like soluble
TNF-a receptor p55 and IL-1 RA by G-CSF (11) seem to
be the main antiin£ammatory e¡ect in pneumonia pa-
tients and are more important clinically than the in£u-
ence of G-CSF on IL-10 orTNF-a (10,17).
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